276 related articles for article (PubMed ID: 22433611)
21. Dapagliflozin: glucuretic action and beyond.
Balakumar P; Sundram K; Dhanaraj SA
Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
[TBL] [Abstract][Full Text] [Related]
22. [Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Oct; 71(10):463-469. PubMed ID: 28383856
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
24. Dapagliflozin: A Review in Type 2 Diabetes.
Dhillon S
Drugs; 2019 Jul; 79(10):1135-1146. PubMed ID: 31236801
[TBL] [Abstract][Full Text] [Related]
25. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Neumiller JJ; White JR; Campbell RK
Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.
Sun YN; Zhou Y; Chen X; Che WS; Leung SW
Syst Rev; 2013 Nov; 2():103. PubMed ID: 24225054
[TBL] [Abstract][Full Text] [Related]
27. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
[TBL] [Abstract][Full Text] [Related]
28. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Mikhail N
South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
[TBL] [Abstract][Full Text] [Related]
29. Dapagliflozin: drug profile and its role in individualized treatment.
Sposetti G; MacKinnon I; Barengo NC
Expert Rev Cardiovasc Ther; 2015 Feb; 13(2):129-39. PubMed ID: 25560982
[TBL] [Abstract][Full Text] [Related]
30. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Riser Taylor S; Harris KB
Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
[TBL] [Abstract][Full Text] [Related]
31. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
[TBL] [Abstract][Full Text] [Related]
32. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
[TBL] [Abstract][Full Text] [Related]
33. Dapagliflozin: a review of its use in patients with type 2 diabetes.
Plosker GL
Drugs; 2014 Dec; 74(18):2191-209. PubMed ID: 25389049
[TBL] [Abstract][Full Text] [Related]
34. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Kilov G; Leow S; Thomas M
Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
[TBL] [Abstract][Full Text] [Related]
35. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Vivian E
Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
[TBL] [Abstract][Full Text] [Related]
36. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Scheen AJ
Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
[TBL] [Abstract][Full Text] [Related]
37. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
38. Durability of response to dapagliflozin: a review of long-term efficacy and safety.
Jabbour S
Curr Med Res Opin; 2017 Sep; 33(9):1685-1696. PubMed ID: 28699798
[TBL] [Abstract][Full Text] [Related]
39. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Komoroski B; Vachharajani N; Feng Y; Li L; Kornhauser D; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):513-9. PubMed ID: 19129749
[TBL] [Abstract][Full Text] [Related]
40. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):647-63. PubMed ID: 24387329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
